| 1 |
Establishing a Clinical Trial Basis Through Nonclinical Evaluation of CR-C003, a First-in-Class Drug Candidate for the Treatment of Inflammatory Bowel Disease |
| Small molecules |
Inflammatory Bowel Disease (IBD); Ulcerative Colitis (UC) and Crohn's Disease (CD) |
CR-E1 (Code name) |
Preclinical |
CUROGEN Technology |
RS-2025-25455442 |
|
| 2 |
Preclinical Study of a Novel BBB penetrant drug for Multiple Sclerosis |
| Small molecules |
Multiple Sclerosis |
**** |
Preclinical |
Daewoong Pharmaceutical |
RS-2025-25455086 |
|
| 3 |
Development of a Novel Multiple Sclerosis Treatment Using the Regulatory T Cell (Treg)-Modulating Peptide KINE-101 |
| rProtein |
Multiple Sclerosis |
**** |
Preclinical |
KINE SCIENCES |
RS-2025-25454784 |
|
| 4 |
Development of mPGES-1 targeted anti-inflammatory mechanism-based arthritis and pain treatment |
| Small molecules |
inflammation and pain-related disorders |
mPGES-1 |
Preclinical |
Kukje pharma |
RS-2025-25454561 |
|
| 5 |
Non-clinical study of OM202-001 from NSDC platform for the treatment of Autoimmune diseases |
| Small molecules |
Ulcerative colitis |
JAK1 |
Preclinical |
Omniamed |
RS-2025-02223486 |
|
| 6 |
Novel Oral Therapeutic Candidate for the Treatment of Chronic Urticaria |
| Small molecules |
Chronic Urticaria |
MRGPRX2 |
Preclinical |
Samjin Pharm. Co., Ltd. |
RS-2025-02173007 |
|
| 7 |
Development of innovative therapeutics that dually protect against bone erosion and inflammatory arthritis |
| Antibody |
Rheumatoid Arthritis |
Integrin αvβ3/Siglec.15 |
Preclinical |
MedPacto, Inc. |
RS-2023-00282595 |
|
| 8 |
Development of a novel topical treatment for atopic dermatitis by modulating TSLP signaling |
| Small molecules |
Atopic dermatitis |
TSLP/TSLPR |
Preclinical |
AmtixBio |
RS-2023-00258738 |
|
| 9 |
Development of BFD1R, an immunomodulatory Live Biotherapeutic Products(LBP) for rheumatoid arthritis |
| Other-Bio. |
Rheumatoid Arthritis |
Gut (Gut.joint axis |
Preclinical |
BIFIDO Co., Ltd |
RS-2023-00258617 |
|
| 10 |
Completion of non-clinical studies and IND authorization for a 3rd generation multiple sclerosis drug candidate based on biased modulation that overcomes the limitations of cardiac side effects |
| Small molecules |
Multiple Sclerosis |
S1P1 |
Preclinical |
CUREVERSE |
RS-2023-00217346 |
|
| 11 |
Non-clinical study of IBD using Live Microbial Gene Therapy based on recombinant microbial Toolbox |
| Other-Bio. |
Ulcerative colitis |
VIP |
Preclinical |
Liveome Inc. |
RS-2023-00217138 |
|
| 12 |
Clinical development of a novel synthetic AHR agonist PB542 as an IBD therapeutics |
| Small molecules |
Crohn's disease |
AhR |
Preclinical |
Parenchyma Biotech |
RS-2022-00165759 |
|
| 13 |
Multi-functional immune-modulating antibody therapeutics for autoimmune disease |
| Antibody |
Rheumatoid Arthritis, Autoimmune Disease |
OX40L, TNF-α |
Preclinical |
IMBiologics |
HN22C0229 |
|
| 14 |
Nonclinical Study for Treatment of IRI Using Bilirubin Nanoparticle (Brixelle) |
| Others-Synth. |
Ischemia reperfusion injury |
ROS |
Preclinical |
BILIX |
HN21C0947 |
|
| 15 |
Development of Complement C5-inhibiting antibody for Autoimmune diseases |
| Antibody |
Paroxysmal nocturnal hemoglobinuria |
C5 |
Preclinical |
ImmunAbs |
HN21C0649 |
|
| 16 |
Development of a therapeutic agent for ulcerative colitis by regulating glycogen metabolism of immune cells and intestinal epithelial cells |
| Small molecules |
Ulcerative colitis |
PYGL |
Preclinical |
INNOVO Therapeutics |
HN21C0604 |
|